European Parliament And Council Of EU "Not Far Apart" On Scrutiny Of High-Risk Devices, IVDs
This article was originally published in SRA
The provision relating to the scrutiny of high-risk products under the proposed EU regulations on medical devices and IVDs has at last made it onto the agenda of the joint talks between the European Parliament, Council of the European Union and the European Commission which were held on December 3.
You may also be interested in...
With fewer than a hundred days left before the EU Medical Device Regulations kick in, Medtech Insight’s executive editor Ashley Yeo and managing editor Amanda Maxwell discuss in this week's podcast growing concerns by medtech industry members that they may not be ready in time to comply with the regulations and may inadvertently run afoul of them.
What will the fall-out of political tensions between the EU and Switzerland mean for notified bodies based in Switzerland, and for the future recognition of CE marks granted in one of the most important medtech markets in Europe?
Eighteen years of free trade threatens to come to a sudden stop, as a result of the stalemate in the market access agreement between Switzerland and the EU. Industry association Swiss Medtech is advising local medtech manufacturers to find notified bodies and authorized representatives based in the EU. However, local company SQS remains confident of its ongoing notified body role.